Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.


  1. Advanced Patent Search
Publication numberUS3717634 A
Publication typeGrant
Publication dateFeb 20, 1973
Filing dateNov 24, 1969
Priority dateNov 24, 1969
Also published asDE2057845A1
Publication numberUS 3717634 A, US 3717634A, US-A-3717634, US3717634 A, US3717634A
InventorsY Wu, J Rayburn
Original AssigneeMead Johnson & Co
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
US 3717634 A
Abstract  available in
Previous page
Next page
Claims  available in
Description  (OCR text may contain errors)

United States Patent C ice 3,717,634 N-(HETEROARCYCLIC)PIPERAZINYLALKYL- AZASPIROALKANEDIONES Yao Hua Wu and James W. Rayburn, Evansville, Ind, assignors to Mead Johnson & Company, Evansville,

Ind. No Drawing. Filed Nov. 24, 1969, Ser. No. 879,604 Int. Cl. C07d /42 US. Cl. 260-4564 N 7 Claims ABSTRACT OF THE DISCLOSURE SUMMARY OF THE INVENTION This invention relates to new compounds characterized by the following general structural formula and the nontoxic pharmaceutically acceptable acid addition salts thereof.

Formula I In the foregoing Formula I, n is the integer 4 or 5. The symbol -A which connects the spiroglutarimide and the N-(heteroarcyolic)piperazine represents a divalent alkylene chain of 2 to 6 carbon atoms inclusive. Said alkylene chain can be straightor branched-chain hydrocarbon grouping in which the ring connecting bonds are on different carbon atoms such as hexamethylene (CH2 CH2 CH2CH CHzCHz) 2-methyl-1,2-propylene OH2C and the like. The piperazine substituent represented by the symbol B is selected from the group consisting of imidazoyl and a heteroarcyclic. Said heteroarcyclic is represented by the symbol:

I WWY Na 3,717,634 Patented Feb. 20,. 1973 wherein W and Y are independently selected from th group consisting of CH and nitrogen. By the term heteroancyclic as used herein, it is meant substituents comprised of nitrogen, carbon, and hydrogen which when taken together form a heteroaromatic system. The R and R substituents of the heteroarcyclic referred to above are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 4 carbon atoms inclusive, alkoxy of from 1 to 4 carbon atoms inclusive, hydroxy, amino, alkylthio of 1 to 4 carbon atoms inclusive, halogen, trifiuoromethyl, alkanoamido of from 1 to 6 carbon atoms inclusive, and alkanesulfonamido of 1 to 6 carbon atoms inclusive. By the term lower alkyl as employed herein it is meant straight or branched chain alkyl radicals including methyl, ethyl, propyl, isopropyl, l-butyl, l-methylpropyl, Z-methylpropyl, and tert.-butyl. Similarly, the alkyl fragment of the alkylthio substituent refers to straight or branched chain radicals described above. Straight or the branched chain alkanes of 1 to 6 carbon atoms inclusive comprise the alkane radical of alkanoamido and alkanesulfonamido groupings.

The term non-toxic pharmaceutically acceptable acid addition salts as used herein refers to a combination of compounds of the present invention with relatively nontoxic inorganic or organic acids. Illustrative of the variety of acids which may be used are sulfuric, phosphoric, hydrochloric, hydrobromic, hydroiodic, sulfamic, methanesulfonic, benzenesulfonic, para-toluenesulfonic, acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, and related acids.

Conversion of the compounds of the present invention to pharmaceutically acceptable acid addition salts is accomplished by admixture of these compounds with substantially one chemical equivalent of any of the various acids hereinbefore defined. Generally the reactions are carried out in an inert solvent. Suitable solvents, merely by way of example, are ethanol, benzene, ethyl acetate, ether, and halogenated hydrocarbons.

Illustrative of the nomenclature employed herein for the naming of the products of this invention are partial structures corresponding to the substituted glutarimide portions of Formula I are shown below with the positions numbered.

| a 7 a 4 e 8-Azaspiro[4.5]decane-7, 9-dione Formula I, n=4

3-Azaspiro[5.5], 4-dioue Formula 1, n=5

General embodiments of the process for the preparation of compounds of the present invention are schematically illustrated below and labeled Method A, Method B and Method C. The use of a particular method to produce compounds embraced by this invention is dietated to a large extent by conditions which will be apparent to those skilled in the art. In practice, the selection of the method used for the preparation of any one compound of the present invention is principally determined by the commercial availability of the necessary intermediates and/or by the case which available compounds can be converted to desired intermediates.

METHOD A O (W HzN-A-N NB Formula I Formula II Formula III METHOD B (4112) N-A-X HN NB FormulaI Formula IV Formula V METHOD C i H2) N-M X-A-N NB FormulaI Formula VI Formula VII In the foregoing reaction schemes, the symbols n, -A, and B have the same meanings as previously defined relative to Formula I. The symbol X refers to the acid residue of a reactive ester grouping such as a chloride, bromide, iodide, sulfate, phosphate, tosylate or mesylate. M comprises an alkali metal salt of the substituted glutarimide and is preferably sodium or potassium.

Method A is carried out by reacting a spiro-substituted glutaric anhydride of Formula II with the l-(w-aminoalkyl) 4 (heteroarcyclic)piperazines of Formula III to provide products of Formula I. Preferably, the reaction is carried out at elevated temperatures in a reaction inert organic solvent. By the term inert organic solvent, as referred to herein is meant any protic or aprotic solvent or diluent which does not enter into the reaction to any substantial degree. Pyridine is the preferred solvent. Temperatures of about 100 C. to about 200 C. are preferred to facilitate completion of the reaction. The duration of the reaction is critical only to the extent of providing maximum yields and reaction periods of from about 16 hr. to as much as 11 days are preferred. The lengthy reaction periods are necessary in some instances to obtain complete conversion of glutaric acid half-amides of Formula VIII which are initially formed when an anhydride of Formula II is combined with an amine of Formula III.

i rins NHAN NB o-orr Formula VIII The glutaric acid half-amides of Formula VIII may be also transformed into Formula I products by heating in boiling acetic anhydride which is a well known standard organic procedure for ring closure useful in the formation of cyclic imides.

Method B is carried out under reaction conditions amply described in literature wherein teritary amines are formed by alkylation of a secondary amine with an alkyl halide, sulfate, phosphate, tosylate, or mesylate. The Formula IV and Formula V intermediates are preferably reacted in an inert liquid reaction medium at temperatures of from about 60 C. to about 200 C. in the presence of a base suitable for use as an acid binding agent. Sodium carbonate is a particularly preferred acid binding agent but other inorganic and tertiary organic base may be employed including other alkali and alkaline earth metal carbonates, bicarbonates, or hydrides and tertiary amines. Reaction periods ranging from about 2 hrs. to approximately 4 days are preferred in order to obtain satisfactory yields of the present compounds. A particularly preferred solvent is n-butanol but any inert reaction medium is generally applicable to use in this reaction. To a large extent, the duration of the reaction period depends upon the temperature and reaction solvent selected. By way of illustration, alkylation is facilitated and the reaction period is appreciably shortened if dimethylformamide is employed as the reaction medium compared to a solvent such as benzene.

Method C is another method useful for preparation of compounds of Formula I. In this method, the spiroglutarirnide metal salt depicted by Formula VI is reacted with substituted piperazines of Formula VII. Standard laboratory procedures are employed in carrying out the reaction such as those described for the alkylation step of the Gabriel synthesis-S. Gabriel, Ber. 20, 2224 (1887). For example, the reactants are combined in an inert reaction medium at temperatures ranging from about 25 C. to 200 C. Preferred solvents for carrying out the reaction are dimethylformamide, acetone, benzene, n-butanol, ethanol and the like.

With respect to the reactants for Methods A, B and C, many of them, including 3,S-tetramethyleneglutaric anhydride, (Formula II, 11:4) are known compounds which are readily available from commercial sources. Others, which are not commercially available, can be prepared in accordance with standard synthetic procedures which are known to those skilled in the art.

Preparation of N (heteroarcyclic)piperazines of Formula V have been described by K. L. Howard at al. in J. Org. Chem., 18, 1484 (1953). Their procedures are applicable to the preparation of other N-(heteroarcyclic)piperazine intermediates not specifically disclosed but which are required for the preparation of compounds embraced in the present invention.

The l-(w-aminoalkyl)-4-(heteroarcyclic)piperazine of Formula III are obtained according to methods described in U.S. Pat. 3,398,151 by alkylation of N- (heteroarcyclic)piperazines of Formula V with haloalkylnitriles to provide 1 (w cyanoalkyl) 4 (heteroarcyclic)piperazine intermediates which are subsequently reduced to the Formula III substituted piperazines. Reduction of the cyano intermediate may be carried out catalytically, preferably with W-6 Raney Nickel catalyst under high pressure, or alternatively with hydrazine and W-6 Raney Nickel.

The intermediate azaspirodecane-and undecanediones of Formula IV having the -A-X- group attached to the nitrogen atom are prepared according to procedures described in U.S. Pat. 3,398,151. Reaction 'of the glutaric anhydrides of Formula II with an alkanolamine of the formula H NAOH are carried out under conditions similar to those described hereinabove for Method A. The resulting intermediate .g'lutarimide has the structure shown for Formula IV wherein X is OH. Esterification of this material is accomplished by conventional techniques well known to the art to provide the intermediate of Formula IV. Preferably, thionyl chloride is reacted with the alcohol precursor of Formula 1V (X=OH) to provide the intermediate wherein X is chlorine. Conventional techniques which are adequately described in the literature are employed to provide the bromides, iodides, phosphates, sulfates, tosylates, and mesylates corresponding to Formula IV.

The piperazine reactant of Formula VII having the X-A- grouping attached to the nitrogen atom is prepared according to standard organic procedures. By way of example, reaction of the piperazines of Formula V with alkanol halides of the Formula HOA-X proides intermediate of Formula VIII.

Formula VIII This intermediate is then esterified according to conventional techniques well known to the art to provide the Formula VH reactants. For instance, thionyl chloride acting upon the compounds of Formula VIII provides the Formula VII intermediate in which X is chlorine. In a similar fashion, bromides, and iodides are prepared. Phosphates, sulfates, tosylates, mesylates corresponding to Formula VII are obtained with conventional laboratory techniques.

General embodiments of the process of the present invention for the preparation of compounds of Formula I as hereinabove described are considered to be a unitary process. Thus, the azaspiroalkanedione of Formula I are prepared in accordance with the unitary process of the present invention by reacting a piperazine of the Formula Y-bi NB Formula IX wherein Y is selected from the group consisting of hydrogen (Formula IXa), H 'NA- (Formula IXb), or XA-- (Formula IXc), and A and X are as hereinbefore defined, with a spirO-glutaric acid anhydride of Formula II.

( fl) n X Formula II wherein n is as hereinbefore defined, when Y is the group H N-A-; or a N-substituted spiro-glutaric acid imide of Formula IV.

( C Hz) 21 X N-A-X Formula IV wherein A and n are as hereinbefore defined and X is a reactive ester group, when Y is hydrogen; or a spiroglutarimide of Formula VI.

Formula VI tion. In the instant case, it has been discovered that N- (heteroarcyclic)piperazine alkyl derivatives of azaspirodecanediones and azaspiroundecanediones are highly active and specific tranquilizing agents and in addition also exhibit anti-emetic properties. Present compounds are improved tranquilizing agents compared to the azaspirodecanediones and azaspiroundecanediones of United States Pat. 3,398,151, in that tranquilizing activity is more potent and specific.

With respect to side effects such as sedative and alphaadrenergic blockade which are exhibited by a number of prominent tranquilizing agents the present compounds are unique in that such adverse reaction is substantially diminished or practically non-existent. By way of illustration, 8- [4- [4-(2-pyrimidinyl)-1-piperazinyl]butyl]- 8 azaspiro[4.5]decane-7,9 dione hydrochloride has only about the alpha-adrenergic blocking activity of the well known tranquilizer, chloropromazine.

Tranquilizing properties of the compounds of this invention can be demonstrated in rats by a shuttle box technique described by I. R. Albert and L. E. .Allen in the Ph'armacologist 4, '152 (1962). This test is designed to differentiate tranquilizing agents from non-specific central nervous system depressants such as sedatives and hypnotics. Tranquilizing effects are observed when the compounds of the present invention are administered intraperitoneally to the rat in dosages ranging from 1.5 to mg./kg. of body weight.

The tranquilizing action of the compounds of the present invention can be demonstrated in Rhesus monkeys by observing general behavioral effects. Intramuscular administration of present compounds to the monkey in dosages ranging from 2 to 16 mg./kg. of body Weight affords tranquilizing effects similar to those produced by chlorpromazine.

The compounds of the present invention are relatively non-toxic compounds. For example, the intraperitoneal 50% lethality dose of 8 [4 [4 (2pyrimidinyl)- 1 piperazinyl1butyl] 8 azaspiro[-4.5]decane-7,9-dione hydrochloride is 146 mg./kg. of body weight in the mouse.

Systemic administration of the compounds of the present invention to mammals in dosages ranging from about 0.01 to 40 mg./kg. of body weight per day induce effective tranquilizing responses in the mammalian recipient. Oral, parenteral and rectal routes are preferred forms of systemic administration. Forms of parenteral administration include intramuscular, intravenous, and subcutaneous administration. Those skilled in the art will recognize that the dosage of the compounds of the present invention will vary with the form and mode of administration and in some instances with the particular compound chosen. Generally, it will be found that when a compound of the present invention is administered orally, a larger quantity of the active agent is required to produce the same effect as a smaller quantity thereof which is given parenterally. It is generally preferred to administer the compounds of this invention at a concentration level that will produce effective tranquilizing effects without causing any harmful or deleterious side effects.

For pharmaceutical purposes, the compounds of Formula I may be administered to mammals in the form of free bases or in the form of non-toxic acid addition salts. In the free base form, the compounds are relatively insoluble in water but are soluble in most organic sol vents such as lower alkyl alcohols, esters, acetones, chloroform and the like. The present compounds in the form their acid addition salts are, in general, soluble in water and methanol but relatively insoluble in solvents such as benzene, ether, petroleum ether and the like. In either the free base or the acid addition salt form, the compounds of Formula I may be compounded and formulated into pharmaceutical compositions and unit dosage suitable for systemic administration. Organic or inorganic Examples of representative compounds of the present invention prepared according to Procedure 1 are indicated in Table I.

TABLE I.-8-[4 (N-HETEROARCYCLIC)-l-PIPERAZINYLALKYIJ-B-AZASPIRO[4.51DECANE-73-DIONE PRODUCTS Product Base Hydrochloride Analyses Ex. B.P., 0. Percent No. Method 11 Hot. (mm. g) yield M.P., O. Crystn.solvent Formula C H N Cl 1 A 2 208 -2U9 5 Eula-I101 CzoHggN4Og-HC1 61.11 7.25 14.26 8.81

2 A 4 Same as above (a 76 172173.5 Z-butanone C H Mm-HCI 63.01 7.89 13.55 8.29

N 3 2 2302 90 200207 Absolute ethanol CnHzrNsOa-HCI 58.00 7.23 17.75 0.03

4 B 3 Same as above 214-215 Absolute ethanol-amen. CzoHzpNgOrHCl 59.06 7.30 17.24 l- 5 A i do 61 201.5-20215 Absolute ethanol ommlmol-nci 60.29 7.41 16.60 8.48 s A 5 do 23 39 52 188.5190.5 Methanolethyl acetate" caramel-H01 60.44 7.93 10.01

7 B 3 23 59 mas-234.5 Ethanol oflnammnm 00.12 7.73 13.01 7.98


used herein it is meant forms of administration such as METHOD B oral, parenteral and rectal. Pharmaceutical compositions considered within the scope of this invention may take the form of tablets, powder, granules, capsules, suspensions, solutions, suppositories, elixirs, ointments and the like. Unit dosages ranging from about 1 to 500 mg. are employed. Suitable pharmaceutical carriers comprise both solids and liquids such as corn starch, lactose, calcium phosphate, stearic acid, polyethylene glycol, water, sesame seed oil, peanut oil, propylene glycol, and the like.

DESCRIPTION OF THE PREFERRED EMBODIMENTS The following examples are illustrative of the process and products of the present invention and are not to be construed as limitations of this invention, many variations of which are possible without departing from the spirit and scope thereof.

METHOD A Procedure l.-Condensation with Substituted Glutaric Anhydride.A mixture of 0.1 mole of the substituted glutaric anhydride (Formula II), 0.1 mole of l-(w-aminoalkyl) 4 (heterocycle)piperazine (Formula 111), and 300 ml. of pyridine is refluxed until imide formation is complete. The degree of reaction is readily followed by taking an aliquot portion of the reaction mixture, removing the solvent, and obtaining the infrared absorption spectrum of the residue. When reaction is complete, the spectrum exhibits typical infrared imide bands at 1700 and 1710 cm? whereas if incomplete, the infrared spectrum contains amide and carboxyl absorption bands at 1680, .1760, and 3300 cm.-

The azaspiroalkanedione product is purified as the free base by stripping oi the pyridine solvent and crystallizing the residue from a suitable solvent or by vacuum distillation thereof.

Suitable acid addition salts of the product are prepared by treating an ethanol solution of the free base with an equi-molar amount of the appropriate acid.

Procedure 2.-Alkylation of N(heteroarcyclic)piperazines.-A mixture of 4.9 g. (0.02 mole) of 8-[3- chloro- 1-propyl)-8-azaspiro [4.5] decane-7,9di0ne, 3 .3 g. (0.02 mole) prepared in the manner of US. Pat. 3,398,- 151, N-(2-pyrimidyl)piperazine, and 2.2 g. (0.02 mole) of sodium carbonate in 75 ml. of n-butanol is refluxed for three days and filtered. The filtrate is concentrated in vacuo and the residue taken up in ml. of benzene. Addition of 4.0 ml. of 5.0 N ethanolic hydrogen chlo ride to the benzene solution of the free base provides the product 8-[3-[4-(2-pyrimidinyl)-l-piperazinyllpropyl]-8-azaspiro[4.5]decane7,9-dione as a hydrochloride salt which is collected and crystallized from absolute ethanol-ether, yield 3.4 g., M.P. 214-215 C. (corn).

Examples of representative products of this invention and physical properties thereof prepared according to Method B are listed in Table 1.

METHOD C Procedure 3.Alkylation of Azaspiroalkaneimides.-- A solution of 0.1 mole of 3,3-tetramethyleneglutarimide in methanol ml.) is treated with 0.1 mole of sodium methoxide. The solvent is removed in vacuo to provide a residue consisting of the sodium salt of 3,3-tetramethyleneglutarimide which without further purification is combined with 0.1 mole of 1-(2-chlorobutyl)-4-(pyrimidiny1) piperazine in 150 ml. of n-butanol. The mixture is refluxed for a period of time of sufiicient duration to provide approximately 0.1 mole of precipitated sodium chloride as a by-product. Isolation of the product by standard laboratory procedures provide 8-[3-[4-(2-pyrimidinyl) -lpiperazinyl1propyl1-8 azaspiro[4.5]decane 7,9-dione which is also a product of Procedure 2.

Examples 8-28.Additional exemplification of compounds of the present invention is given in Table II along with the mode of preparation according to Method A, Method B, or Method C and the appropriate intermediates. Although only a single method of preparation TABLE II-Contlnued Product Ex. No. 11 A Het. Method Intermediates 21 4 (CHz)4- O-C(CH;); B 8-(4-ehlorobutyl)-8-azaspir0I4.5]decane-7,9-dlone and l-[2-(4-tert.-butylpyrimidinympiperazine.

22 4 -(CH1)4- B 8-(4-chlorobutyl)-8-azaspiro[4.5]decane-7,Q-dione and 1-[2-(6-trlfluoromethylpyridinympiperazine.

23....- 4 -(CH=); N A 3,3-tetramethyleneglutar1e anhydrlde and 1-(4-aminobutyD-4-[2-(1,3,5-

N triazinyl)]piperazine.

24"-.. 4 (CH NO; C 3, B-t-etramethyleneglutarimlde and 1-(2-chloroethyl)4-[2-(4-nltm4, 3, 5-

N mazinympiperazine.

25.-- 4 (CHz)4- N A 3, 3-tetramethyleneglutarlc anhydride and 1-(4-aminobutyD-4-[2-(3-propionylamidopyridinyb]piperazine.

NH 0 01H;

26..." 4 (CH:) NHSOICH; A 3, 3-tetramethyleneglutarlc anhydride and 1-(4-amlnobutyl) -4-[4-(2, 6

dimethanesulfonamidopyrimidinyl)1p1perazine. N.-

NHSOaCHa 27-.." 4 (OH )4 N A 3, a-tetramethyleneglutarlc anhydride and 1-(4-amlnobutyl)-4-[2-(4-hydroxy- H pyrimldinyl) piperazine.

28..-" -(CHa)4- A 3, s-pentamethyleneglutaric anhydride and 1-(4-aminobutyD-4-(2-pyridinybpiperazine.

8 [4-[4-(4,6dimethyl-2-py1imidinyl)-l-piperazinyllbntyll-ileazaspiro[4.5]decane-7,Q-dione hydrochloride. M.P. 216.5217.5 0. (corn), crystallized from absolute ethanol-anhydrous ether. Analysis-Salad. for CzaHauClNaOz! C, 61.38; H, 8.06; N, 15.56. Found: C, 61.26; H, 8.10; N, 15.53.

Procedure 4.1-(3cyanopropyl)-4-(2 pyrimidinyl)- piperazine.-A mixture of l-(2-pyrimidinyl)pipera2ine (6.0 g., 0.04 mole), 4.6 g., (0.044 mole) of 3-chloropropionitrile and sodium carbonate (4.24 g., 0.04 mole) in m1. of n-butanol is gently refluxed for 16 hours. The reaction mixture is concentrated in vacuo and the residual oil dissolved in about 100 ml. of cyclohexane.

On standing a white crystalline material separates which is crystallized from cyclohexane to provide 6.5 g. (yield of the cyano intermediate, M.P. 56.658 C. Representative examples of cyano intermediates useful in Procedure 5 along with information relative to the preparation thereof according to Procedure 4 are listed in Table III.


number Hats 11 Yield (mm. Hg) M.P., 03" Formula C H N 1 1 32 u uN4 same as abm 3 92 %?85} 1 47-49 0.3mm.

3 1 8O 1 98400 CmHnNs 59. 12 6. 62 34. 77

4 Same as above 3 7O 1 56-58 CnHuH; 2.04 7.31 30.08 5- do 4 80 1 77-78 C15H19N5 63.49 7. 62 28. 41

6 NH, 3 87 5 191-192 CflHflN? 37.84

TABLE IIICntlnued Analysis Intermediate B.P., 0. number Het 11 Yield (mm. Hg) M.P., 0. Formula C H N 7 CHBO a 46{ ounflmo, 56.90 1.01 23.41


3 uooj 109-110 CiaHmNu 59.94 7.66 32.48

1 Crystalline solvent is cyclohexane.

2 Crystalline solvent is methanol.

! Crystalline solent is ethyl acetate-Skellysolve F. 4 Crude.

Procedure 5.1-(4-aminobutyl) 4 (2 pyrimidinyl) piperazine.(A) A solution of 11.5 g. (0.05 mole) of 1-(3-cyanopropyl)-4-(2-pyrimidinyl)piperazine in 150 ml. of absolute ethanol is saturated with ammonia. W-6 Raney nickel catalyst is added and the mixture hydrogenated under 1200 psi. When the hydrogenation is completed the mixture is filtered and the residual oil distilled under reduced pressure to provide 8.2 g. (70%) of l-(4-aminobutyl)-4-(2-pyrimidinyl)piperazine.

Reduction of cyano intermediates of Procedure 4 in the manner described for Procedure 5 or alternatively by reduction with hydrazine and Raney nickel provide the amino intermediates of Formula III. The following procedure is illustrative of hydrazine and Raney nickel reductions.

(B) Hydrazine hydrate 85% (640 ml.) is added drop- Wise to 4-[4-(2-pyrimidinyl) l piperazinylJbutyronitrile (189.8 g., 0.82 mole), Raney nickel (190 g.Wet with water, activated by washing with 2-propanol) and 2-propanol (1.4 liter) in 2 hours at reflux. The reaction is stirred for 5 minutes, filtered, concentrated in vacuo and the residual material distilled to yield 168.2 g. (87%) of 1-(4-aminobutyl)-4-(Z-pyrimidinyl)piperazine, B.P. 143- 6" C. at 0.1 mm. (11 15582).

Procedure 6.Solution for parenteral injection-The azaspiroalkanedione compounds of the present invention are formulated for parenteral administration according to the following example. A sterile solution suitable for intravenous injection is prepared by dissolving 21.9 g. of 8-[4- [4-(2-pyrimidinyl) 1 piperazinyl]butyl] 8 azaspiro[4.5]decane-7,9-dione hydrochloride in 2 liters of water for injection, USP. The solution is adjusted to pH 4.2 with 0.1 N-sodium hydroxide. After adjusting the pH, the solution is sterilized by passage through a bacteriological filter and ml. glass ampules aseptically filled in order to provide 10 mg. of active ingredient per ampule.

Procedure 7.Tablets.The azaspiroalkanedione compounds of the present invention are compounded into tablets in accord with the following example.

Material: Amount, grams 8-[4-[4-(2 pyrimidinyl) 1 piperazinyHbutyl] -8-azaspiro [4.5 decane-7,9-dione hydrochloride 54.8 Magnesium stearate 1.3 Corn starch 12.4 Corn starch pregelatinized 1.3 Lactose 180.2

a compound having the formula n is the integer 4 or 5;

A is a divalent straight or branched alkylene chain of 2 to 6 carbon atoms inclusive and connects the nitrogen atoms as shown through at least 2 carbon atoms;

B is

wherein one of W and Y is CH and the other is nitrogen,

R and R are independently selected from the group consisting of hydrogen, lower alkyl from 1 to 4 carbon atoms inclusive, and lower alkoxy of from 1 to 4 carbon atoms inclusive;

References Cited UNITED STATES PATENTS 8/1968 Yao Hua Wu 260-268 PH OTHER REFERENCES Howard et al., J. Org. Chem. 18, 1484 (1953).

ALEX MAZEL, Primary Examiner J. TOVAR, Assistant Examiner U.S. Cl. X.R.

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3907801 *Dec 6, 1972Sep 23, 1975Mead Johnson & CoN-{8 (4-pyridyl-piperazino)-alkyl{9 -azaspiroalkanediones
US4123538 *Aug 30, 1977Oct 31, 1978Mcneil Laboratories, Incorporated(2-Amino-2-oxoethoxy)acetic acid compounds, compositions and methods
US4182763 *May 22, 1978Jan 8, 1980Mead Johnson & CompanyBuspirone anti-anxiety method
US4305944 *Sep 8, 1980Dec 15, 1981Mead Johnson & CompanyN-[(4-[3-cyano substituted pyridyl]piperazino)alkyl]-azaspirodecanediones
US4320131 *Mar 16, 1981Mar 16, 1982Mead Johnson & CompanyN-[(4-Phenyl-1,2,3,6-tetrahydropyridin-1-yl)alkylene]azaspiroalkanediones and N-[(4-hydroxy-4-phenylpiperidin-1-yl)alkylene]azaspiroalkanediones
US4351939 *Oct 16, 1980Sep 28, 1982Mead Johnson & CompanySpiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4361565 *Dec 28, 1981Nov 30, 1982Mead Johnson & Company2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyridines
US4367335 *Aug 3, 1981Jan 4, 1983Mead Johnson & CompanyThiazolidinylalkylene piperazine derivatives
US4409223 *Aug 6, 1982Oct 11, 1983Riblet Leslie AAnxiolytic method
US4411901 *Dec 23, 1981Oct 25, 1983Mead Johnson & CompanyBenzisothiazole and benzisoxazole piperazine derivatives
US4417049 *Jul 19, 1982Nov 22, 1983Mead Johnson & CompanySpiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4423049 *Dec 28, 1981Dec 27, 1983Mead Johnson & Company2-[4-[(4,4-Dialkyl-2,6-piperidinedion-1-yl)butyl]-1-piperazinyl]pyrimidines
US4452799 *Aug 5, 1983Jun 5, 1984Mead Johnson & CompanyBenzisothiazole and benzisoxazole piperazine derivatives
US4456756 *Aug 3, 1981Jun 26, 1984Mead Johnson & CompanySpirothiazolidinyl piperazine derivatives
US4507303 *Dec 1, 1982Mar 26, 1985Sumitomo Chemical Company, LimitedSuccinimide derivatives, compositions and method of use
US4515947 *Aug 11, 1982May 7, 1985Eastman Kodak CompanyCyanoalkylpiperazines and methods for their preparation and use
US4524206 *Sep 12, 1983Jun 18, 1985Mead Johnson & Company1-Heteroaryl-4-(2,5-pyrrolidinedion-1-yl)alkyl)piperazine derivatives
US4543355 *Jan 8, 1985Sep 24, 1985Sumitomo Chemical Company, LimitedSubstituted succinimides, compositions and method of use
US4562255 *Mar 30, 1984Dec 31, 1985American Home Products CorporationSubstituted bi-alicyclic imides
US4581357 *Mar 26, 1984Apr 8, 1986Mead Johnson & CompanyAntipsychotic 5-fluoro-pyrimidin-2-yl piperazine compound
US4598078 *Oct 19, 1983Jul 1, 1986Sumitomo Chemical Company, LimitedN-(substituted piperazinyl) alkylbicyclic succinimide derivatives
US4612312 *Jun 13, 1985Sep 16, 1986Merrell Dow Pharmaceuticals Inc.Glutarimide antianxiety and antihypertensive agents
US4619930 *Jan 16, 1985Oct 28, 1986Bristol-Myers CompanyAntipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use
US4620002 *Aug 11, 1982Oct 28, 1986Eastman Kodak Company2-pyrimidyl alkanesulfonates
US4620006 *Aug 11, 1982Oct 28, 1986Eastman Kodak CompanyAcid salts of 1-(cyanoalkyl)-4-guanylpiperazines
US4634703 *Oct 25, 1985Jan 6, 1987Bristol-Myers CompanyMethod for alleviation of panic disorders
US4640921 *Feb 4, 1986Feb 3, 1987Bristol-MyersTreatment of sexual dysfunction with buspirone
US4668687 *Nov 19, 1985May 26, 1987Bristol-Myers CompanyPsychogeriatric 1-(2-pyrimidinyl)piperazinyl derivatives of 1-pyrrolidin-2-ones
US4677104 *Jul 16, 1986Jun 30, 1987Bristol-Myers CompanyAntipsychotic fused-ring pyridinylpiperazine derivatives
US4687772 *Oct 7, 1986Aug 18, 1987Bristol-Myers CompanyMethod for improvement of short term memory
US4737500 *Jun 20, 1986Apr 12, 1988Sandoz Pharm. Corp.1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and -tetrahydropyridines useful as anxiolytic, psychogeriatric, antidepressant and antischizophrenic agents
US4745117 *Mar 27, 1986May 17, 1988Sumitomo Pharmaceuticals Company, LimitedImide derivatives and compositions for use as antipsychotic agents
US4777173 *Mar 25, 1987Oct 11, 1988Bristol-Myers CompanyMethod for treatment of alcohol abuse
US4810789 *Aug 28, 1987Mar 7, 1989Bristol-Myers CompanyProcess for buspirone hydrochloride polymorphic crystalline form conversion
US4812461 *Sep 25, 1987Mar 14, 1989Sumitomo Pharmaceuticals Company, LimitedImide derivatives and their use in the treatment psychosis
US4812567 *Dec 17, 1986Mar 14, 1989American Home Products CorporationPolycyclic spiroimides with psychotropic activity
US4826843 *Aug 28, 1987May 2, 1989Bristol-MyersCerebral function enhancing diazinylpiperidine derivatives
US4859671 *Jul 8, 1988Aug 22, 1989American Home Products Corporation2-substituted 1,2-benzisothiazol-3(2H)-one 1,1-dioxide useful as an anxiolytic agent
US4880930 *Nov 30, 1987Nov 14, 1989New James SPsychotropic acyclic amide derivatives
US4892879 *Feb 2, 1988Jan 9, 1990Sandoz Pharm. Corp.1-substituted-4-(thiazolyl-2-)-piperazines, -piperidines and tetrahydro-pyridines useful as anxioltic, psychogeriatric, antisepressant and antischiziphrenic agents
US5001130 *Feb 18, 1988Mar 19, 1991Bristol-Myers CompanyPsychotropic heterobicycloalkylpiperazine derivatives
US5015646 *Aug 28, 1987May 14, 1991Bristol-Myers Squibb Co.Pharmaceutically useful polymorphic modification of buspirone
US5077295 *Sep 16, 1988Dec 31, 1991Pfizer Inc.Antipsychoic 4-(4-(3-benzisothiazolyl)-1-piperazinyl)buytl bridged bicycle imides
US5098904 *Jun 27, 1990Mar 24, 1992Bristol-Myers Squibb CompanyCerebral function enhancing pyrimidinyl derivatives
US5116970 *Dec 20, 1990May 26, 1992New James SPsychotropic heterobicycloalkylpiperazine derivatives: 2. fused pyridazinones
US5137894 *Dec 5, 1991Aug 11, 1992New James S4-(4-Piperidinyl-thieno[3,2-c]pyridine derivatives of n-alkylglutarimides
US5153206 *Dec 2, 1988Oct 6, 1992Pfizer Inc.Arylpiperidine derivatives
US5187277 *Aug 23, 1991Feb 16, 1993Komissarov Igor VDL-3-[4-[4-(2-pyridyl)-1-piperazinyl]-butyl]-1,8,8-trimethyl-3-azabicyclo[(3]octane-2,4-dione having psychotropic and antiemetic effect
US5242911 *May 23, 1989Sep 7, 1993Pfizer Inc.Bridged bicyclic imides as anxiolytics and antidepressants
US5338738 *Apr 19, 1993Aug 16, 1994Bristol-Myers Squibb CompanyCerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines
US5391570 *Oct 14, 1993Feb 21, 1995Bristol-Myers SquibbAminomethyl-benzodioxane and benzopyran serotonergic agents
US5407938 *Oct 14, 1993Apr 18, 1995Israel Institute For Biological ResearchCertain 1-methyl-piperidine-4-spiro-4'-(1'-3'-oxazolines) and corresponding -(1',3' thiazolines)
US5431922 *Oct 28, 1993Jul 11, 1995Bristol-Myers Squibb CompanyMethod for administration of buspirone
US5468749 *Jun 16, 1989Nov 21, 1995Gawin; Frank H.Method for treatment of substance addiction
US5484788 *Mar 26, 1993Jan 16, 1996Beth Israel Hospital AssociationBuspirone as a systemic immunosuppressant
US5496847 *Jan 24, 1995Mar 5, 1996Bristol-Myers Squibb Co.Aminomethyl-benzodioxane and benzopyran serotonergic agents
US5521313 *May 5, 1994May 28, 1996Bristol-Myers Squibb CompanyProcess for preparing certain azapirones
US5538985 *Jan 24, 1995Jul 23, 1996Mitsui Toatsu Chemicals, Inc.Pyrrolidinone derivatives
US5602128 *Dec 2, 1994Feb 11, 1997American Home Products CorporationN-heterocycloalkyl carboxamides as serotonergic agents
US5631017 *Mar 26, 1993May 20, 1997Beth Israel Deaconess Medical Center, Inc.Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5633009 *Nov 12, 1993May 27, 1997Sano CorporationTransdermal administration of azapirones
US5637314 *Jun 7, 1995Jun 10, 1997Beth Israel Deaconess Medical Center, Inc.Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US5658941 *Dec 13, 1995Aug 19, 1997Bristol-Myers Squibb CompanyAminomethyl-benzodioxane and benzopyran serotonergic agents
US5817331 *Jun 7, 1995Oct 6, 1998Sano CorporationTransdermal administration of azapirones
US5837280 *Jun 7, 1995Nov 17, 1998Sano CorporationTransdermal administration of azapirones
US5852029 *Jan 18, 1996Dec 22, 1998Israel Institute For Biological ResearchAza spiro compounds acting on the cholinergic system with muscarinic agonist activity
US5922341 *Oct 28, 1997Jul 13, 1999Vivus, IncorporatedLocal administration of pharmacologically active agents to treat premature ejaculation
US6008222 *Nov 6, 1997Dec 28, 1999Bristol-Myers Squibb CompanyMethod for oral administration of buspirone and nefazodone
US6037360 *Oct 28, 1997Mar 14, 2000Vivus, IncorporatedAdministration of 5-HT3 receptor antagonists to treat premature ejaculation
US6150365 *Jun 6, 2000Nov 21, 2000Bristol-Myers Squibb CompanyAnxiety method
US6228864Oct 27, 1998May 8, 2001Vivus, Inc.Administration of 5-HT receptor agonists and antagonists, to treat premature ejaculation
US6306859Mar 1, 2000Oct 23, 2001American Home Products CorporationN-substituted imide derivatives with serotonergic activity
US6312717Jun 14, 1999Nov 6, 2001Bristol-Myers Squibb CompanyMethod for treatment of anxiety and depression
US6313114Dec 30, 1999Nov 6, 2001American Home Products Corp3,4-Dihydro-2H-benzo[1,4]oxazinyl-methyl)-[3-(1H-indol-3yl)-alkyl]- amines
US6376494Nov 28, 2000Apr 23, 2002American Home Products CorporationCycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6432956May 3, 1991Aug 13, 2002William C. DementMethod for treatment of sleep apneas
US6518272Mar 27, 2002Feb 11, 2003WyethCycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US6566361May 17, 2001May 20, 2003Laboratories, UpsaAzapirone pain treatment
US6828324Feb 20, 2004Dec 7, 2004WyethBranched adamantyl and noradamantyl aryl-and aralkylpiperazines with serotonin 5-HT1A activity
US6831084Nov 6, 2000Dec 14, 2004WyethBranched adamantyl and noradamantyl aryl- and aralkylpiperazines with serotonin 5-HT1A activity
US6864262Nov 16, 2001Mar 8, 2005Eli Lilly And Company1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
US7049330Jan 10, 2003May 23, 2006WyethCycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US7067518Aug 29, 2003Jun 27, 2006WyethPyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US7470797Aug 12, 2004Dec 30, 2008Bristol-Myers Squibb CompanyFused heterocyclic imido and amido compounds
US7517904Jul 7, 2005Apr 14, 2009Bristol-Myers Squibb CompanyFused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US8735578Sep 22, 2011May 27, 2014Aché Laboratórios Farmacêuticos S.A.Compounds and pharmaceutical compositions for treating disorders associated with the 5-HT1A and 5-HT2A receptors
US8759346Mar 26, 2010Jun 24, 2014Novartis AgOrganic compounds
US8933090Oct 19, 2010Jan 13, 2015Novartis Ag1-aza-bicyclo[3.3.1]nonanes
US9012451May 2, 2012Apr 21, 2015Novartis AgAza-bicycloalkyl ethers and their use as ALPHA7-nachr agonists
US9186359Oct 13, 2011Nov 17, 2015Contera Pharma ApsCombinations of serotonin receptor agonists for treatment of movement disorders
US9206181May 23, 2014Dec 8, 2015Novartis Ag1-aza-bicyclo[3.3.1] non-4-yl)-[5-(1H-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-AChR for the treatment of psychotic and neurodegenerative disorders
US20030069251 *Jul 23, 2002Apr 10, 2003Yevich Joseph P.Antianxiety composition
US20030139449 *Jan 10, 2003Jul 24, 2003WyethCycloalkyl-substituted aryl-piperazines, piperidines and tetrahydropyridines as serotonergic agents
US20040067962 *Nov 16, 2001Apr 8, 2004Schaus John Mehnert1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof
US20040147581 *Nov 5, 2003Jul 29, 2004Pharmacia CorporationMethod of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US20050107395 *Aug 29, 2003May 19, 2005Greenblatt Lynne P.Pyridinyl-methyl-ethyl cyclohexanecarboxamides as serotonergic agents
US20050137206 *Oct 20, 2004Jun 23, 2005Yevich Joseph P.Method for treatment of anxiety and depression
US20050272799 *Jul 7, 2005Dec 8, 2005Salvati Mark EFused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20060223832 *Aug 12, 2004Oct 5, 2006Salvati Mark EFused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
US20090023744 *Jun 17, 2008Jan 22, 2009The General Hospital CorporationCombination therapy for depression
US20100184775 *Jul 22, 2010Novartis AgOrganic compounds
US20110034475 *Feb 10, 2011Novartis Ag1-aza-bicyclo[3.3.1]nonanes
DE2920739A1 *May 22, 1979Dec 6, 1979Bristol Myers CoVerwendung von 8-eckige klammer auf 4-eckige klammer auf 4-(2-pyrimidinyl)-1piperazinyl eckige klammer zu -butyl eckige klammer zu -8-azaspiro eckige klammer auf 4.5 eckige klammer zu decan-7,9-dion
DE2920739C2 *May 22, 1979Aug 8, 1991Bristol-Myers Squibb Co. (N.D.Ges.D.Staates Delaware), New York, N.Y., UsTitle not available
DE3141256A1 *Oct 16, 1981Aug 19, 1982Bristol Myers CoSpiro-quaternaere ammoniumhalogenide und n-(2-pyrimidinyl)-piperazinylalkylazaspiroalkandion-verfahren
DE3149011A1 *Dec 10, 1981Jul 15, 1982Bristol Myers CoVerfahren zur herstellung von buspiron
DE3248138A1 *Dec 27, 1982Jul 7, 1983Bristol Myers Co2-(4-(4,4-dialkyl-2,6-piperidindion-1-yl)butyl)-1-piperazinyl)pyridine, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten
DE3248160A1 *Dec 27, 1982Jul 7, 1983Bristol Myers Co2-(4-((4,4-dialkyl-2,6-piperidindion-1-yl)-butyl)-1-piperazinyl)pyrimidine, verfahren zu ihrer herstellung und pharmazeutische mittel, die diese verbindungen enthalten
DE3622842A1 *Jul 8, 1986Mar 5, 1987Bristol Myers CoDiazinylpiperidin-derivate, verfahren zu ihrer herstellung und pharmazeutische mittel
EP0236931A2 *Mar 4, 1987Sep 16, 1987Merrell Dow Pharmaceuticals Inc.Aromatic omega-alkylimino-tetrahydro-6H-1,3-Thiazin-6-one derivatives
EP0238905A2 *Mar 4, 1987Sep 30, 1987Merrell Dow Pharmaceuticals Inc.4-(2-pyrimidinyl)-1-piperazinyl heterocyclic carbonyl derivatives
EP0304941A1 *Aug 26, 1988Mar 1, 1989Bristol-Myers Squibb CompanyPharmaceutically useful polymorphic modification of buspirone
EP0313535A1 *Oct 17, 1988Apr 26, 1989Bristol-Myers Squibb CompanyOral formulation of buspirone and salts thereof
EP0314363A2 *Oct 17, 1988May 3, 1989Pfizer Inc.Anti-anxiety agents
EP0395192A2 *Apr 27, 1990Oct 31, 1990Alkaloida Vegyeszeti GyarProcess for the preparation of 8-(4-(4-pyrimidin-2-yl-piperazinyl)-butyl)-8-aza-spiro(4.5)decane-7,9-dione (buspiron)
EP0447345A2 *Feb 11, 1991Sep 18, 1991Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. (Faes)New Azaspyro [4.5] decane-7,9-dione derivatives
EP0655449A1 *Sep 23, 1994May 31, 1995Jin Ro LimitedA process for preparing N-( 2-pyrimidyl) piperazinyl butyl imides
EP0680961A1 *Apr 13, 1995Nov 8, 1995Bristol-Myers Squibb CompanyImproved, large-scale process for azapirone synthesis
EP2336129A1Jun 17, 2005Jun 22, 2011Novartis AG1-aza-bicyclo[3.3.1]nonanes
EP2354141A1Dec 14, 2006Aug 10, 2011Novartis AG(1-aza-bicyclo[3.3.1]non-4-yl)-[5-(1h-indol-5-yl)-heteroaryl]-amines as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
EP2361914A1Dec 14, 2006Aug 31, 2011Novartis AG[(1h-indol-5-yl)-heteroaryloxy]-(1-aza-bicyclo[3.3.1]nonanes as cholinergic ligands of the n-achr for the treatment of psychotic and neurodegenrative disorders.
EP2457911A1Jul 13, 2005May 30, 2012Novartis AG3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nAChR ligands for the treatment of CNS diseases.
EP2463278A1Apr 10, 2006Jun 13, 2012Novartis AG1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
EP2468732A1Apr 10, 2006Jun 27, 2012Novartis AG1H-Quinazoline-2,4-diones
EP2476671A1Apr 10, 2006Jul 18, 2012Novartis AG1H-Quinazoline-2,4-diones
WO1984000752A1 *Jun 13, 1983Mar 1, 1984Eastman Kodak CoAcid salts of 1-(cyanoalkyl)-4-guanylpiperazines and methods for their preparation and use
WO1987004621A1 *Jan 30, 1987Aug 13, 1987Ekkehard OthmerTreatment of sexual dysfunction with buspirone
WO1989003676A1 *Oct 17, 1988May 5, 1989Aktiebolaget AstraOral formulation of buspirone and salts thereof
WO1990002552A1 *Sep 16, 1988Mar 22, 1990Pfizer Inc.Antipsychotic 4-[4-(3-benzisothiazolyl)-1-piperazinyl]butyl bridged bicyclic imides
WO1996006846A1 *Jul 28, 1995Mar 7, 1996Universidad Complutense De MadridNew arylpiperazine derivatives
WO2000006163A1 *Jun 15, 1999Feb 10, 2000Bristol-Myers Squibb CompanyImproved method for treatment of sleep-related respiratory disorders
WO2006108591A1Apr 10, 2006Oct 19, 2006Novartis Ag1h-quinaz0line-2,4-diones and their use as ampa-receptor ligands
WO2012037634A1Sep 22, 2011Mar 29, 2012Aché Laboratórios Farmacêuticos S.A.Compounds and pharmaceutical compositions for treating disorders associated with the 5-ht1a and 5-ht2a receptors
U.S. Classification544/230, 514/872, 544/209, 544/212
International ClassificationC07D239/24, C07D401/14
Cooperative ClassificationC07D401/14, C07D239/24, Y10S514/872
European ClassificationC07D401/14, C07D239/24